Home/Izun Pharmaceuticals/Jonathan Kalman

JK

Jonathan Kalman

CEO

Izun Pharmaceuticals

Therapeutic Areas

Oral health Women's health Wound healing Oncology supportive care

Izun Pharmaceuticals Pipeline

Drug	Indication	Phase
PeriActive™	Periodontal disease (gingivitis, periodontitis)	Commercial
CURASITE™	Chronic wounds, including diabetic foot ulcers	Commercial
IZN‑6N4	Oral mucositis in cancer patients	Preclinical
GSM Botanical Therapy	Genitourinary Syndrome of Menopause	Preclinical

Leadership Team at Izun Pharmaceuticals

Dr. William Levine

Dr Amy Rosenbluh

Director of Production & Laboratory Manager

View full Izun Pharmaceuticals profile